Drug intelligence / Profile preview

Terpacan

Development stage: Discontinued
Lead developer: Tetra Bio-Pharma
Modality: Small Molecules
Administration: Topical

Overview

**TERPACAN** is a non-prescription topical cream formerly authorized in Canada for hemorrhoid symptom relief. The exact unqualified TERPACAN product listed by Health Canada contained benzocaine 5% w/w and phenylephrine hydrochloride 0.25% w/w. Benzocaine provides local anesthetic activity by inhibiting voltage-gated sodium-channel signaling, while phenylephrine is an alpha-1 adrenergic receptor agonist intended to produce local vasoconstriction. The product was developed under Tetra Bio-Pharma's OTC program and was later listed under Lumiera Health Innovation; its Canadian DIN 02495678 was cancelled pre-market on August 18, 2024. ([health-products.canada.ca](https://health-products.canada.ca/dpd-bdpp/info?code=98556&lang=eng))

Brand names: TERPACAN

Targets

ADRA1A (α1A)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Terpacan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Terpacan.

Explore the full profile